The landscape of the japan generic drug market, however, has changed noticeably over the last decade. The Japanese government has identified growth of the country’s generic drug market as imperative to Japan’s long-term economic health. The Japanese government, recognizing the country’s increasing aging population as well as rising costs of branded drugs has begun instituting healthcare policy changes to cut their expenditures on medical costs. Drug costs account for around a fifth of the country’s total medical expenses and reducing this burden has become a cornerstone of Japan’s health administration policy. Substitution of low-cost generic drugs for innovator products has been identified as a strategy where major savings are possible. Driven by these initiatives, the penetration of generics has grown robustly over the past few years. The government has also made a target towards achieving a generic penetration of 60% by 2018. This is expected to create huge opportunities for both domestic and foreign generic manufacturers in Japan.
The report entitled “Japan Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023” represents an in-depth analysis on the historical, current and future trends in the generic drug market in Japan. This research report serves as an exceptional tool to understand the drivers, sales trends, prescription trends, market structure, competitive landscape, regulations, key players, key drugs, manufacturing and the outlook of generic drug market in Japan. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who want to gain an insight into the market for generic drugs in Japan.
Key Questions Answered:
- What are generic drugs? How are they different from branded drugs?
- How has Japan’s generic drug market performed in recent years?
- How have generic drugs performed compared to branded drugs?
- Who are the key players in the Japanese generic drug market? How have they performed?
- What is the structure of the Japanese generic drug market?
- What is the pricing mechanism of generic drugs in Japan?
- What is the value chain of generic drugs in Japan?
- What are the regulations for generic drugs in Japan?
- How are generic drugs distributed in Japan?
- How are generic drugs manufactured?
- What are the raw material and machinery requirements to manufacture generic drugs?
- What are the drivers and challenges in the Japanese generic drug market?
2 Scope and Methodology
2.1Objectives of the Study
3 Executive Summary
4 Japan Generic Drug Market - Introduction
4.1 What are Generic Drugs?
4.2 Unbranded and Branded Generic Drugs
4.3 Authorized Generic Drugs
5 Why is the Japanese Generic Drug Market so Lucrative
5.1 Blockbuster Drugs Going Off-Patent
5.2 Rising Healthcare Costs Coupled with an Increasing Ageing Population
5.3 Japan Has One of the Lowest Penetration of Generics
5.4 Incentives for Dispensing Generics
5.5 Significant Savings For Payers and Providers
6 Global Generic Drug Market
6.1 Current and Historical Market Trends
6.1.1 Value Trends
6.1.2 Volume Trends
6.2 Market Breakup by Country
6.3 Market Forecast
6.4 Most Prescribed Generic and Branded Drugs
7 Japan Generic Drug Market
7.1 Japan Pharmaceutical Market Performance
7.1.1 Value Trends
7.1.2 Volume Trends
7.1.3 Market Breakup by Type
7.1.4 Market Forecast
7.2 Japan Generic Drug Market Performance
7.2.1 Value Trends
7.2.2 Volume Trends
7.2.3 Market Forecast
8 SWOT Analysis
9 Pricing Mechanism and Profit Margins at Various Levels of Supply Chain
10 Porter’s Five Forces Analysis
10.2Bargaining Power of Buyers
10.3Bargaining Power of Suppliers
10.4Degree of Competition
10.5Threat of New Entrants
10.6Threat of Substitutes
11 Japan Generic Drug Market- Competitive Landscape
11.1 Japan Generic Drug Market - Competitive Structure
11.2 Japan Generic Drug Market - Sales Breakup of Key Players
11.3 Japan Generic Drug Market - Distribution Breakup by Channels
12. Japan Generic Drug Market- Value Chain Analysis
12.1Research and Development
13 Regulations in Japan Generics Industry
13.1 Approval Pathway of a Generic Drug in Japan
13.1.1Master File Scheme for Active Ingredients
13.2.1 MAH (Market Authorization Holder) License for Product Approval
13.2.2 FMA (Foreign Manufacturer Accredited) Certification for Product Approval
13.2.3 DMF (Drug Master File) Registration
13.2.4 GMP (Good Manufacturing Practices) Certification
13.2.5 Manufacturer’s License
14 Japan Generic Drug Market: Key Success Factors
15 Japan Generic Drug Market: Road Blocks
16 Requirements for Setting up a Generic Drug Manufacturing Plant
16.1 Manufacturing Process
16.2 Raw Material Requirements
16.3 Machinery and Infrastructure Requirements
17 Japan Generic Drug Market - Key Company Profiles